HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients.

Front Oncol · 2022 · PMC9887140 · PMID 36733354

Europe PMC DOI

hedged sentence

0.2630

closest p · 5.3× alpha

0.2630

boldest claim

The sentences

showed a trendp=0.263not close (p > 0.1)

CNS metastases Compared with patients with HER2-negative SGCs, the HER2-positive group showed a trend towards higher prevalence of CNS metastases: 40% ( 10 ) vs. 24% ( 9 ) (p=0.263).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.